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esponsibility of Xi’Abstract A sensitive, accurate and selective liquid chromatography–tandem mass spectrometry method
(LC–MS/MS) was developed and validated for the simultaneous quantitation of atorvastatin (AT) and its
equipotent hydroxyl metabolites, 2-hydroxy atorvastatin (2-AT) and 4-hydroxy atorvastatin (4-AT), in
human plasma. Electrospray ionization (ESI) interface in negative ion mode was selected to improve the
selectivity and the sensitivity required for this application. Additionally, a solid phase extraction (SPE)
step was performed to reduce any ion-suppression and/or enhancement effects. The separation of all
compounds was achieved in less than 6 min using a C18 reverse-phase fused-core
s column and a mobile
phase, composed of a mixture of 0.005% formic acid in water:acetonitrile:methanol (35:25:40, v/v/v), in
isocratic mode at a ﬂow rate of 0.6 mL/min. The method has lower limit of quantitation (LLOQ) of
0.050 ng/mL for all analytes. The method has shown tremendous reproducibility, with intra- and inter-day
precision less than 6.6%, and intra- and inter-day accuracy within 74.3% of nominal values, for all
analytes, and has proved to be highly reliable for the analysis of clinical samples.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.sity. Production and hosting by Else
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an Jiaotong University.1. Introduction
Atorvastatin (AT) is a synthetic competitive inhibitor of 3-hydroxy-
3-methylglutaryl coenzyme A (HMG-CoA) reductase, which cata-
lyzes the conversion of HMG-CoA to mevalonate, an early and a
rate limiting step in cholesterol biosynthesis. Among statins it has
established a prominent place in therapeutics that can achievevier B.V. All rights reserved.
LC–MS/MS estimation of atorvastatin 27relatively large reduction in plasma cholesterol levels and, thereby,
ameliorate vascular atherosclerosis and reduce cardiovascular mor-
bidity and mortality [1,2]. It is administered in the active lipid-
lowering acid form, atorvastatin acid, and gets completely absorbed
upon oral administration [3,4]. It has low oral bioavailability of
about 12–14% due to its rapid presystemic clearance in the gut wall
as well as metabolism in the liver [5].
AT remains highly bound to plasma protein (Z98%) and has
the elimination half-life of approximately 14 h, which is consider-
ably longer than that of most other statins [6]. It gets extensively
metabolized to 2- and 4-hydroxylated derivatives and various
β-oxidation products mediated through cytochrome P450 3A4
(CYP3A4) metabolism, and around 70% of the HMG-CoA
reductase inhibition associated with AT has been ascribed to its
2- and 4-hydroxylated metabolites [7,8]. In-vivo AT and its major
hydroxylated metabolites, 2-AT and 4-AT, are present in equili-
brium with their corresponding inactive lactone forms (Fig. 1) and
it is mainly the lactone form that undergoes metabolism by
CYP3A4, because of a signiﬁcant higher afﬁnity for CYP3A4
compared with that of the acid form. Lactonization of the acid
form and hydrolysis of the lactone form to the open-acid form of
AT have been suggested to be catalyzed by uridine diphosphate
(UDP)-glucuronosyltransferase (UGTs) and esterases (paraoxo-
nases) enzyme, respectively [9,10]. This interconversion phenom-
enon also takes place in the samples during storage, sample
preparation stages, detection, and seriously impacts the accuracy of
results during conduct of pharmacokinetic studies. In order to
characterize the pharmacokinetic parameters accurately, it is
essential to avoid their ex-vivo interconversion. The use of an
appropriate anticoagulant, lowering sample temperature and pH of
the plasma, could signiﬁcantly affect the interconversion between
lactone and acid forms.
A variety of analytical methods including radioimmunoassay
[11], high performance liquid chromatography coupled with
electrochemical or ultra violet (UV) detection [12,13], enzyme
inhibition bioassay [14], gas chromatography–mass spectrometry
(GC–MS) [15], liquid chromatography–mass spectrometry
(LC–MS) [16], liquid chromatography–tandem mass spectrometry
(LC–MS/MS) [17–23], and ultra-high performance liquid chro-
matography–tandem mass spectrometric detection (UPLC–MS/
MS) [24] have been reported for the analysis of AT alone and
its metabolites in biological matrix. The published methods with
UV or electrochemical detection, radioimmunoassay and enzyme
inhibition assay were proved to be time consuming and have
higher limit of quantiﬁcation. Although the GC–MS methodology
meets the desired LLOQ, it requires complex derivatization of
analytes prior to analysis, which makes the sample preparation
more laborious. Most of the reported LC–MS, UPLC–MS/MS and
LC–MS/MS methods utilize electrospray ionization interface in
positive ion mode towards the quantiﬁcation of AT and its
metabolites. These methods either require higher plasma aliquot
volume (4300 mL), tedious and time-consuming extraction pro-
cedures and/or are not sensitive enough for the estimation of active
metabolites concentration for pharmacokinetic study after admin-
istration of low dose AT. Macwan et al. [25] reported a method,
comparable in terms of sensitivity with the present work, with
LLOQ of 0.050 ng/mL for AT and its ﬁve metabolites using 50 mL
of plasma. This method employed protein precipitation extraction
with a chromatographic run time of 7 min.
In this research we report for the ﬁrst time a stability indicating,
sensitive and precise LC–MS/MS methodology for simultaneous
determination of AT and its equipotent hydroxyl metabolites withan ESI interface in negative ion mode. The validated method was
successfully applied to a clinical pharmacokinetic study following
an oral administration of AT in healthy adult male volunteers with
successful incurred sample reanalysis (ISR).2. Experimental
2.1. Chemicals and materials
AT, 2-AT, 4-AT, and their respective deuterium labeled, -D5, analog
(AT-D5, 2-AT-D5, and 4-AT-D5) were procured from TLC Pharma
Chem. Canada, whereas standard compounds of AT lactone, 2-AT
lactone, and 4-AT lactone were purchased from TRC Canada.
Ammonium acetate, acetonitrile and methanol of LC–MS grade were
obtained from FLUKA (Sigma-Aldrich, Steinheim, USA). Analytical
grade ortho-phosphoric acid (OPA) and hydrochloric acid (HCL)
were purchased from Fisher Scientiﬁc (Mumbai, India). Oasiss HLB
(30 mg, 1 cc), solid phase extraction (SPE) cartridges were obtained
from Waters (Milford, MA, USA). All aqueous solutions and buffers
were prepared using water that was puriﬁed using Milli-Qs Gradient
A10s (Millipore, Molscheim, France). Human plasma matrix lots for
method development, validation, to prepare calibration standards and
quality control (QC) samples were obtained from clinical unit of
Ranbaxy Research Laboratories (Delhi, India).2.2. LC–MS/MS instrumentation and operating conditions
The liquid chromatography separation was performed using a
Shimadzu scientiﬁc instruments (Shimadzu Corporation; Kyoto,
Japan) comprising of two LC-20AD pumps, a cooling autosampler
(SIL 20AC), a column oven of temperature control (CTO-20AC)
and a CBM 20A controller. Chromatography separation of analytes
and their corresponding D5-ISTDs was accomplished within
6.0 min using an Ascentiss Express C18 (75 mm 4.6 mm,
2.7 mm; Supelco, Bellefonte, Pennsylvania, USA) column and a
mobile phase consisting of 0.005% formic acid in water:acetonitrile:
methanol (35:25:40, v/v/v) in isocratic mode at 0.6 mL/min. The
column and autosampler temperature were kept at 45 1C and 5 1C,
respectively.
An Applied Biosystems Sciex API 4000 (MDS-Sciexs, Concord,
Canada) consisted of an ESI interface was operated in negative ion
mode. Quantiﬁcation was carried out using multiple reaction monitor-
ing (MRM) mode of the transitions m/z 557.4-278.1 for AT, m/z
562.4-283.2 for AT-D5, m/z 573.5-278.1 for 2-AT, m/z 578.5-
283.1 for 2-AT-D5, m/z 573.4-278.2 for 4-AT and m/z 578.5-
283.2 for 4-AT-D5, with dwell time set at 150 ms per transition.
Nitrogen was used as the nebulizer, auxiliary, collision and curtain
gases. The main working source/gas parameters of the mass spectro-
meter were optimized and maintained as follows: collision activated
dissociation (CAD) gas, 7; curtain gas (CUR), 20; gas 1 (nebulizer
gas), 50; gas 2 (heater gas), 55; turbo ionspray (IS) voltage, 4500 V;
and source temperature, 500 1C. Other optimized compound para-
meters for monitoring analytes were set as follows: declustering
potential (DP), 70 V; entrance potential (EP), 14 V; collision
energy (CE), 60 V; and collision cell exit potential (CXP), 18 V.
Calibration curves were constructed by calculating the analyte to
internal standard (ISTD) peak area ratio (y) against analyte con-
centrations (x). Data acquisition and processing were performed
using Analyst version 1.4.1 software (MDS-Sciexs, Canada).
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quality control samples
Stock solutions of AT, 2-AT, 4-AT and their respective -D5 ISTDs
were prepared separately by dissolving the accurately weighed
compounds in methanol to obtain a ﬁnal concentration of 1 mg/mL.
The prepared stock solutions were stored at 20 1C until use.
Similarly, stock solutions of AT lactone, 2-AT lactone and 4-AT
lactone were prepared as and when required in acetonitrile to obtain
a ﬁnal concentration of 1 mg/mL.
Two sets of working solutions were then prepared in methanol–
water (50:50, v/v) for the preparation of calibration standards. One
set contained a mixture of AT and 2-AT at nine concentration
levels in the range 5.007–10,013.765 ng/mL for AT and 5.010–
10,019.831 ng/mL for 2-AT, and another set contained 4-AT at
nine concentration levels in the range 5.001–500.063 ng/mL.
Calibrations standards containing a mixture of all three analytes
were prepared by 1% addition of each working solution in human
blank plasma (e.g., at each concentration level, 10 mL of each of
the two working solutions was added to 1 mL human plasma).
This resulted in the calibration range 0.050–100.138 ng/mL for
AT, 0.050–100.198 ng/mL for 2-AT and 0.050–5.001 ng/mL for
4-AT. Simultaneously quality control samples were prepared in the
same manner as that of calibration standards in bulk from the
working solutions at four levels “High/HQC” (80.201 ng/mL for AT,
79.520 ng/mL for 2-AT, and 3.950 ng/mL for 4-AT), “Middle/MQC”
(12.815 ng/mL for AT, 12.723 ng/mL for 2-AT and 1.101 ng/mL for
4-AT), “Low/LQC” (0.125 ng/mL for AT, 0.127 ng/mL for 2-AT,
and 0.126 ng/mL for 4-AT), and “LOQQC” (0.050 ng/mL for AT, 2-
AT, and 4-AT). In order to evaluate the stability in the presence of
inactive lactone metabolites, lactone fortiﬁed QC samples were also
prepared at two levels, high and low. The working solutions for the
lactone metabolites were prepared in acetonitrile:water (50:50, v/v).
The fortiﬁed low QC (F-LQC) samples contained AT lactone, 2-AT
lactone, and 4-AT lactone at levels 3.0, 5.0 and 7.0 times higher than
their respective acid form, whereas the fortiﬁed high QC (F-HQC)
samples contained AT lactone, 2-AT lactone, and 4-AT lactone at
levels 1.5, 3.0 and 4.0 times higher than their respective acid form. The
amount of lactone metabolite was chosen so as to be representative of
incurred/clinical samples [26].
A modiﬁed procedure towards stabilizing the analytes in the
biological matrix was applied, wherein a 2% of plasma, from each
spiked calibration standards, QC samples as well as incurred/
clinical samples during sample collection, was replaced with the
buffer solution (10% v/v, OPA in water). A maximum of 5%
dilution of the plasma matrix was allowed. If not used, the
calibration standards and quality control samples were stored in
aliquots at 50 1C until analysis. The stock solutions used for the
preparation of quality control samples were different from the one
used for the preparation of calibration curve standards.
A working solution containing the three ISTDs was prepared in
methanol:water (50:50, v/v) at concentrations of 25.000 ng/mL for
AT-D5 and 50.000 ng/mL for 2-AT-D5 and 4-AT-D5. All the
above mentioned working solutions were prepared and stored
under low light conditions in ice-cold water bath until use.2.4. SPE procedure
Plasma samples frozen at 50 1C were thawed on the day of
extraction in ice-cold water bath followed by vortexing to ensure
homogeneity. Eppendorf pipette was used to aliquot 200 mL ofplasma samples into appropriately labeled polypropylene tubes
and plasma samples were mixed with 50 mL of ISTDs working
solution as well as 400 mL of water titrated to pH 4.170.1 with
formic acid. After brief stirring with vortex mixer, the samples
were centrifuged at 4000 rpm for 5 min. The supernatant was then
loaded onto Waters; Oasis, HLB disposable extraction cartridge
(30 mg, 1 cc). The cartridges were previously conditioned with
0.500 mL of methanol and then with 0.500 mL of water. Washing
step was performed using 1 mL of 30% methanol in water and
analytes were eluted with 0.500 mL of methanol twice. The
eluents were then evaporated to dryness using a Zymark TurboVap
LV evaporator (Caliper, Hopkinton, MA, USA) and reconstituted
with 100 mL of reconstitution solution consisting of acetonitrile:
methanol:water titrated to pH 4.170.1 with formic acid (20:20:60,
v/v/v). The reconstituted samples were transferred to autosampler
glass vials. 20 mL of sample was injected into the LC–MS/MS
system for analysis.
The whole sample preparation was carried out in ice-cold water
bath (excluding vortex mixing, SPE and drying) and under low
light conditions, to avoid temperature and light-induced degrada-
tion of the analytes.
2.5. Interconversion
The interconversion between the acid and lactone forms of the
analytes was evaluated under different experimental conditions.
Since this methodology involves estimation of acid form of
analytes, the change in peak area response of quantiﬁable acids
between the stability and comparison samples was attributed to the
interconversion. The percent change in acid form of analyte was
calculated as: % change¼ (sc)/c 100, in which s and c
represent the average peak area response of the analytes obtained
from stability and comparison samples (n¼4), respectively.
2.5.1. Effect of plasma temperature
Two sets of plasma samples were prepared: set-1 contains all three
acid compounds, whereas set-2 contains all three lactone com-
pounds. The aliquots of spiked samples were taken and kept at
room temperature as well as in ice cold water bath for about 4 h
acting as stability samples and evaluated against the comparison
samples prepared at the end of 4 h.2.5.2. Effect of anticoagulants
The role of various anticoagulants like lithium heparin, citrate
phosphate dextrose adenine (CPDA), sodium ﬂuoride (NaF) and
ethylenediaminetetraacetic acid tripotassium salt (K3EDTA)
towards restricting the conversion of lactone compounds to acid
compounds was compared. Plasma sets containing the antic-
oagulant were taken separately and spiked with all three lactone
compounds and kept on bench for about 4 h acting as stability
samples and evaluated against the comparison samples prepared at
the end of 4 h.
2.5.3. Effect of plasma pH
Several different strengths of acidiﬁed buffer were assessed to
restrict the interconversion between the acid and lactone forms of
analytes. The buffer solutions tested include 10% OPA in water,
50% OPA in water and 1 M HCL in water. Two sets of plasma
samples were prepared to evaluate the interconversion: set-1
contains all three acid compounds, whereas set-2 contains all
LC–MS/MS estimation of atorvastatin 29three lactone compounds. The spiked plasma samples were treated
with these buffer solutions separately and kept at room tempera-
ture for about 4 h acting as stability samples and evaluated against
the comparison samples prepared at the end of 4 h.
2.5.4. Effect of storage on bench top for different time and
multiple freeze–thaw cycles
Three sets of plasma samples were prepared: set-1 contains all three
acid compounds; set-2 contains all three acid and lactone com-
pounds; set-3 contains all three acid and lactone compounds in
buffered plasma. Four replicates of samples were prepared in each
set, and analyzed after being kept at room temperature for different
time and after exposing to multiple freeze–thaw cycles. The
changing trends of analyte peak area response were plotted against
respective variables.
2.6. Method validation
A full method validation was performed according to guidelines
set by the USFDA [27]. The validation of this procedure was
performed in order to evaluate the method in terms of selectivity,
sensitivity, linearity, accuracy, precision, recovery, matrix effect,
and stability of analyte during both short-term sample processing
and long-term storage.
2.6.1. Selectivity
The selectivity of the assay was evaluated by analyzing blank
plasma samples (six normal, one lipemic and one hemolyzed) from
eight different donors and spiked plasma samples at LLOQ level.
The peak area of the co-eluting components should be less than
20% and 5% those of the analytes and the corresponding ISTDs,
respectively.
2.6.2. Linearity and sensitivity
The linearity of the method was determined by analysis of
standard plots associated with a nine point calibration curve.
Calibration curves from accepted three precision and accuracy
batches were used to establish linearity. Peak area ratios of analyte/
ISTD obtained from MRM were utilized for the construction of
calibration curves, using weighted (1/x2) linear least squares
regression of the plasma concentrations and the measured peak
area ratios. Back-calculations were made from these curves to
determine the concentration of analytes in each calibration
standards and the resulting calculated parameters were used to
determine concentrations of analyte in quality control or unknown
samples. The correlation coefﬁcient (r)40.99 was desirable for all
the calibration curves. The lowest standard on the calibration curve
was to be accepted as the LLOQ, if the analyte response was at
least ﬁve times more than that of drug-free (blank) extracted
plasma. In addition, the analyte peak of LLOQ sample should be
identiﬁable, discrete, and reproducible with accuracy within
720% and a precision r20%. The deviation of standards other
than LLOQ from the nominal concentration should not be more
than 715%.
2.6.3. Accuracy and precision
Intra- and inter-day accuracies were expressed as a percentage of
deviation from the respective nominal value and the precision of
the assay was measured by the percent coefﬁcient of variation
(%CV) at concentrations. Intra-day precision and accuracy was
assessed by analyzing six replicates of the quality control samplesat four levels during a single analytical run. The inter-day
precision and accuracy was assessed by analyzing 18 replicates
of the quality control samples at each level through three precision
and accuracy batches runs on 2 consecutive validation days. The
deviation at each concentration level from the nominal concentra-
tion was expected to be within 715% except limit of quantitation
quality control (LOQQC), for which it should not be more than
20%. Similarly, the mean accuracy should not deviate by 715%
except for the LOQQC where it can be 720% of the nominal
concentration.
2.6.4. Recovery
Recovery was estimated at three QC concentration levels (low,
medium, and high) by comparing the mean peak area of all the
analytes in the QC samples (n¼6) with those of neat solutions
(n¼3) containing analytes at concentrations equivalent to those
obtained in the ﬁnal extracted concentration in the QC samples.
The recoveries of D5-ISTDs were measured in a similar manner
using their corresponding medium QC samples as reference.
2.6.5. Matrix effect and matrix factor
Matrix effect was assayed at two concentration levels (LOQQC
and HQC). Six different plasma lots (four normal, one hemolyzed,
one lipemic) free of any signiﬁcant interference at the retention
time (RT) of analytes and ISTDs, were selected and spiked with
the working solutions of LOQQC and HQC. Spiked samples from
each plasma lot were processed in duplicate and quantitated
against freshly spiked calibration curve. The matrix effect is
validated to be nulliﬁed if the accuracy and precision does not
deviate by 715% for HQC and 720% for LOQQC of the
nominal concentration.
The matrix factor is deﬁned as the peak area response in the
presence of matrix ions versus the peak area response in the
absence of matrix ions. Since this method involved terminal drying
step, biological matrix samples were prepared by reconstituting the
post-extracted blank plasma samples with neat solutions (n¼3)
containing analytes and ISTDs at equivalent concentration repre-
senting the ﬁnal extracted concentration for the analytes (low,
medium, and high QC level) and ISTDs. The control samples were
the same neat solutions prepared in reconstitution solution. Matrix
factor was evaluated using six different blank plasma lots
(four normal, one hemolyzed, one lipemic) and determined by
measuring the respective mean peak area response (absolute matrix
factor) and mean analyte/ISTD peak area ratio (ISTD normalized
matrix factor) of biological matrix sample against the mean peak
area response and mean analyte/ISTD peak area ratio of neat
solutions.
2.6.6. Stability
Stability of analytes was evaluated using lactone fortiﬁed QC (L-QC)
and unfortiﬁed QC samples. Bench-top stability was evaluated in ice
cold water bath for 6 h, which exceeds the residence time of the
sample processing procedures. The freeze–thaw stability was evaluated
after undergoing three freeze (at 50 1C)–thaw (ice cold water bath)
cycles. Long-term stability was assessed after storage of the test
samples at 50 1C for 103 days. The autosampler storage stability was
determined by storing the reconstituted QC samples for 49 h under
autosampler condition (maintained at 5 1C) before being analyzed. All
stability exercises were performed against freshly spiked calibration
standards processed along with freshly spiked unfortiﬁed comparison
QC (UC-QC) samples at low and high concentrations (n¼4) for
P. Partani et al.30determining the absolute stability of analytes. Absolute stability was
calculated as follows: % absolute stability¼ (average concentration of
stability samples/average concentration of comparison samplesC.
F.) 100; C.F.¼concentration of stability sample/concentration of
comparison sample. The analyte was considered stable at each
concentration if the mean calculated concentration of stability samples
does not deviate by 715% of the mean calculated concentration of
comparison quality control samples.
The working solutions and stock solutions of analytes and
ISTDs were also evaluated for their stability at room temperature
for about 9 h and at 20 1C for 17 days, respectively.
2.6.7. Method application
An open label, balanced, randomized, two-treatment, two-period, two-
sequence, single-dose, crossover design was used for the assessment of
pharmacokinetics and bioequivalence. Eighteen healthy adult male
volunteers who gave written informed consent took part in this study.
The study was approved by ethics committee of Institutional Review
Board at Majeedia hospital (New Delhi, India). After an overnight fast
of at least 10 h, all subjects were given a single oral dose of AT 80 mg
tablet of Ranbaxy and Lipitors tablet (containing AT calcium 80 mg)
from Pﬁzer laboratories of Pﬁzer. Inc. USA during each period of the
study. Blood samples were collected in pre-chilled K3EDTA vacutai-
ners at pre-dose (in-duplicate), 0.167, 0.333, 0.500, 0.750, 1.000,
1.250, 1.500, 1.750, 2.000, 2.250, 2.500, 2.750, 3.000, 4.000, 5.000,
6.000, 7.000, 8.000, 12.000, 16.000, 24.000, 36.000, 48.000, 60.000,
72.000 and 96.000 h post dose in each period. The plasma was
immediately separated by centrifugation as well as stabilized with the
buffer solution and stored at 50 1C until analysis. The pharmacoki-
netics parameters were calculated by a non-compartmental analysis
using WinNonlin Professional software (Version 5.0, Pharsight Corp.,
Mountain View, CA, USA). The peak plasma concentration (Cmax)
and time to reach Cmax (Tmax) were read directly from the experimental
data. The total area under the plasma concentration–time curve from
time zero to inﬁnity (AUC0-1) and from time zero to the last
measurable concentration (AUC0-t) was calculated using the trape-
zoidal rule-extrapolation method.
An incurred sample reanalysis was performed on ninety-six
sample points selected randomly from the study population. The
basic objective of ISR was to reconﬁrm the initial values and to
demonstrate that the assay is reproducible. The conformity of the
original result with the ISR sample is calculated as a % difference.
The % difference should be within 20% for at least 67% or 2/3rd
of the total reanalyzed incurred samples [28] [% differen-
ce¼absolute (reanalyzed valueoriginal value)/average of reana-
lyzed and original value 100%].3. Results and discussion
3.1. Method development
3.1.1. Mass spectrometry optimization
During the early stage of method development, both ESI and
atmospheric pressure chemical ionization sources were investi-
gated. ESI offered much higher signal intensities for all target
analytes than the latter and was thus chosen as the ionization.
The ﬁrst LC–MS/MS tests to select the optimum MS/MS
parameters and the appropriate ions were carried out by syringe
pump infusion of standard solution at a concentration of 25 ng/mL
in mobile phase, with monitoring of MS intensity. The ionization
efﬁciencies of AT and its active metabolites were almost similar.These analytes contain an amino group that can receive protons
and an aliphatic carboxylic group that can release proton. Hence,
these analytes show responses in either ESI positive or ESI
negative ion mode. It was found that the best results in terms of
peak area and peak height were obtained in ESI negative ion mode
than in ESI positive ion mode due to their readiness to lose proton
from the carboxylic group. Moreover, the negative ion mode is
usually considered as more speciﬁc, being relatively low the
number of compounds undergoing negative ionization mode, and
consequently less subjected to ion suppression [29,30]. In this
context ESI negative ion mode was chosen. Fig. 2 shows the
product ion spectra of the analytes and their deuterated ISTDs, as
well as their tentative fragmentation proﬁles. The product ion is
formed by the loss of 3,5-dihydroxy-heptanoic acid side chain
along with phenylaminocarbonyl group. Deuterated ISTDs shared
similar fragmentation patterns with their non-labeled counterparts.
For MRM detection, the most stable and appropriate fragment ions
produced by the analytes and ISTDs were selected. The lactone
compounds are devoid of carboxylic functional group and thus
show poor response in ESI negative ion mode compared to their
acid counterparts (data not shown). Different additives of varying
strength were added to the mobile phase, so as to obtain higher
abundance of deprotonated parent ion of analytes and ISTDs. Use
of formic acid over additives like acetic acid, ammonium formate,
ammonium acetate, etc., in mobile phase enhances the occurrence
of [MH] and eventually results in an optimal area response for
analytes and ISTDs.3.1.2. Liquid chromatography conditions
To select the starting conditions towards optimizing the LC
parameters, we have paid attention to previous work, relating to
the estimation of AT and its metabolites. In most of these studies,
widely accepted C18 based analytical columns were employed to
achieve good resolution with satisfying peak shape and peak
symmetry. Thus a number of reversed-phase columns, such as
Atlantis™ dC18, Ascentis
s C18, Symmetry
s C18, YMC basic C18,
and Ascentiss Express C18 were tested to achieve optimal
resolution, selectivity, and efﬁciency with a short running time.
Ascentiss Express C18 was chosen as an analytical column
because it offers a really high separation power with modest
operating pressure and involves the usual compromise of chroma-
tographic characteristics. This technology of small superﬁcially
porous particles, also called as Fused-cores, gains wider popu-
larity towards improving separation efﬁciencies and speed without
reducing particle size. The very high efﬁciency of the fused-core
particles is likely to be due to their extremely narrow particle size
distribution, lower internal porosity, smaller diffusion distance,
improved mass transfer, and better packing. Columns of 2.7 mm
fused core particles show efﬁciencies almost equivalent to those
containing totally porous sub-2 mm particles while maintaining
robustness of the column [31].
The optimization procedure was focused on the mobile phase
composition, column oven temperature, and injection volume.
Firstly, several mobile phases composed of acidiﬁed water with
appropriate organic phase (acetonitrile/methanol) in different ratios
were tested. Initially, when acetonitrile was used, the acid metabo-
lites exhibited satisfactory sensitivity; however, a good separation
was not achieved between the acid and lactone compounds and
matrix peaks affected the determination of 4-AT. Whereas the
desired separation could be easily accomplished when methanol
was used as organic phase; unfortunately, this leads to partial loss in
Fig. 1 Chemical structure and metabolic pathways of AT and its metabolites.
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trile and methanol in terms of signal sensitivity and separation
efﬁciency, the mixture of methanol and acetonitrile was reasonably
chosen as organic phase. After several tests had been performed, it
was possible to obtain the desired resolution and sensitivity with the
mobile phase composed of 0.005% of formic acid in water:
acetonitrile:methanol (35:25:40, v/v/v). Simultaneously, tests were
carried out to study the inﬂuence of the column temperature
(between 30 and 65 1C, at an increment of 5 1C) on retention time
and injection volume (from 10 to 50 mL) towards enhancing the
sensitivity of the method. The best results were achieved when
20 mL was injected and column oven maintained at 45 1C. The set of
samples prepared in reconstitution solution shows symmetric peak
shape and produces higher signal–noise ratio (S/N) compared to
those prepared in mobile phase.
Under the chromatographic conditions described above, the D5-
ISTDs were eluted at the same retention time as their corresponding
unlabeled analytes. The retention times were 1.8, 3.2 and 4.1 min
for 4-AT, 2-AT, and AT, respectively (Fig. 3). The retention times
were 2.1, 3.8 and 5.0 min for 4-AT lactone, 2-AT lactone, and AT
lactone, respectively (data not shown). The difference in elution
pattern achieved chromatographically beneﬁted towards minimizing
the potential interference to analytes, due to the ion-source
fragmentation, from the labile lactone metabolites.
3.1.3. Sample preparation
During method development different options were evaluated to
optimize sample cleanup so as to eliminate possible matrix inter-ferences, concentrate the sample and obtain a sample as clean as
possible to preserve the life of the analytical column. Firstly, the
simplest and fastest protein precipitation (PPT) method for
preparing samples was carried out; unfortunately, it did not result
in a very clean extract and produced higher background noise with
poor sensitivity. Secondly, liquid–liquid extraction was evaluated
towards isolation of analytes from biological matrix that yields
rather clean extracts compared to PPT, but the procedures involved
was cumbersome and ﬁnd multiple pitfalls. We needed to put in
multiple extraction steps to increase analyte recovery and to get
cleaner extracts; but failed to improve extraction efﬁciency for the
polar acid metabolites speciﬁcally 4-AT. Finally, SPE was
employed that always results in signiﬁcant lower lipid levels, a
signiﬁcant source of matrix, compared to PPT and often produces
excellent recoveries for polar and non-polar analytes. Taking this
into account, we employed Oasis HLB SPE disposable cartridge to
extract analytes from plasma samples. Use of acidiﬁed water
during sample preparation helps in breaking the drug–protein
binding partially alongside stabilizing the analytes in biological
matrix. Moreover, 30% methanol in water during washing step
helps to remove polar matrix interferences from cartridge bed.
The extraction procedure described here offers a rapid way to
isolate analytes and ISTDs from plasma matrix and provides scope
for automation.
3.1.4. Interconversion
During the initial stages of method development, the inﬂuence of
temperature on stability of the acid and lactone forms of analytes
Fig. 2 The product ion spectra of: (A) AT, (B) AT-D5, (C) 2-AT, (D) 2-AT-D5, (E) 4-AT, and (F) 4-AT-D5.
P. Partani et al.32was evaluated in plasma. The samples containing the three lactone
compounds show a degradation of about 55% and 30% in 4 h
when kept at room temperature and in ice-cold water bath,
respectively, evidenced by an increased in peak area response of
their respective acid in stability samples. On the contrary, samples
containing the three acid compounds were found stable under both
conditions demonstrated by an unchanged peak area response for
acids in stability samples.
The inﬂuence of different anticoagulants on the conversion of
lactone compounds to acid compounds was evaluated and it was
observed that the use of anticoagulants like EDTA or NaF acts a
good inhibitor of ester hydrolysis and restricts the conversion of
lactone compounds to acid compounds certainly to a good extent
compared to other tested anticoagulants. Simultaneously, the
inﬂuence of different strengths of acidiﬁed buffer on the inter-
conversion between acid and lactone compounds was investigated
and shows that the addition of different acidiﬁed buffers to plasma
could signiﬁcantly affect the interconversion. When plasma pH was
not controlled, i.e., at normal plasma pH the lactone compounds
would easily get converted to acid compounds. However, if plasma
pH was made too acidic a decrease in peak area response for the acid
compounds would be observed; reasonably the acid compounds
would have got converted to lactone compounds. The test result
obtained therein (data not shown) validates that an immediate
addition of 2% buffer solution (10% v/v, OPA in water) during
sample collection in clinic as well as CC standard and QC sample
preparation in lab, restricts the interconversion efﬁciently.
The test results of multiple freeze–thaw cycles and bench top
storage for different time on the interconversion and/or stability of
acid and lactone compounds (data not shown), indicated a
prominent degradation of lactone compounds to acid compounds
in the plasma samples (set-2) which were not stabilized with
acidiﬁed buffer solution, evidenced by a signiﬁcant increase inthe area response of acid compounds. Whereas the comparison
between set-1 and set-3 data indicates that there was no conversion
and/or degradation of lactone compounds to acid compounds seen
in plasma samples treated with acidiﬁed buffer solution.
It is reported that apart from the enzymes in plasma, changing
plasma pH which increases upon storage may results in degradation of
drug and drug metabolites after samples have been collected and
during sample processing [32]. Thus, it is supposed that use of an
anticoagulant with esterase inhibitory property, simultaneously main-
taining a stable pH in plasma alongside lowering sample temperature,
is reasonable to restrict the instability problem completely as described
in this research work.
3.2. Method validation
3.2.1. Selectivity
Fig. 3 shows the typical MRM chromatograms of blank plasma;
plasma spiked with ISTDs; plasma spiked with AT, 2-AT and 4-
AT at LLOQ (0.050 ng/mL for each analyte) and ISTDs; and
plasma spiked with AT, 2-AT and 4-AT at ULOQ and ISTDs.
Interfering peaks from endogenous components were not observed
at the retention time of all the analytes and ISTDs.
3.2.2. Linearity and sensitivity
The linear regressions of the peak area ratios versus concentrations
were ﬁtted over the range of 0.050–100.138 ng/mL for AT, 0.050–
100.198 ng/mL for 2-AT and 0.050–5.001 ng/mL for 4-AT in human
plasma. The typical equations of the calibration curves were as follows:
AT: y¼0.607xþ0.0407, r¼0.9991; 2-AT: y¼0.356xþ0.0283,
r¼0.9989; 4-AT: y¼0.388xþ0.0048, r¼0.9989; where y represents
the ratio of analyte peak area to that of ISTD and x represents the
nominal plasma concentration.
LC–MS/MS estimation of atorvastatin 33The LLOQ for this method was 0.050 ng/mL for AT and its
hydroxyl metabolites. The achieved LLOQ was sufﬁcient to study
the pharmacokinetic proﬁles of AT, 2-AT and 4-AT following an
oral administration of AT. Sensitivity of the method was estab-
lished using LOQQC samples analyzed in three consecutive
validation runs. Wherein, precision values obtained were below
6.6% and accuracy values were within 74.3%.
3.2.3. Accuracy and precision
Eighteen replicates of the QC samples from three consecutive
validation runs were used to evaluate precision and accuracy at
each concentration level. The intra- and inter-day precision and
accuracy values of the QC samples are summarized in Table 1.
The intra-day precision for all the analytes was less than 5.2%, the
inter-day precision was less than 6.6%, and the intra- and inter-day
accuracy values were within ± 5.7%. The intra- and inter-day
precision and accuracy values were within the acceptable range.
The method was thus judged to be accurate and reproducible.
3.2.4. Recovery
At low, middle, and high QC concentration levels the mean
recovery values were 76.3%, 78.0%, and 77.9% for AT; 73.1%,
75.1%, and 74.7% for 2-AT; and 75.7%, 72.6%, and 74.4% for
4-AT, respectively. In addition, the mean extraction recovery for
AT-D5, 2-AT-D5, and 4-AT-D5 was 79.9%, 78.3%, and 71.1%,
respectively. The result indicates that the extraction efﬁciency for
analytes and ISTDs using SPE was satisfactory, consistent and was
not concentration dependent.
3.2.5. Matrix effect and matrix factor
Matrix effect as well as matrix factor on the presented method was
evaluated following the procedures described above. Results
obtained therein indicate that no additional variations in plasma
concentration due to the use of different plasma lots were observed
as accuracy values at LOQQC and HQC levels were within the
acceptable range (data not shown). Hence, the concentration of the
analyte obtained from clinical study samples should therefore be
considered as reliable.Table 1 Intra- and inter-day precision and accuracy data for the det
Compound Spiked concentration (ng/mL) Intra-day (n¼6)
Mean (ng/mL) Accura
AT 0.050 0.049 98.3
0.125 0.126 100.7
12.815 13.313 103.9
80.201 78.703 98.1
2-AT 0.050 0.053 105.7
0.127 0.129 101.2
12.723 12.704 99.8
79.520 77.709 97.7
4-AT 0.050 0.048 95.7
0.126 0.121 96.2
1.101 1.083 98.3
3.950 3.935 99.6The average absolute matrix factor values are 0.92, 0.95, and
0.94 for AT; 0.92, 0.97, and 0.98 for 2-AT, and 1.08, 1.09 and
1.05 for 4-AT at low, middle and high QC levels, respectively.
Whereas the ISTD normalized matrix factor values are 1.01, 1.01,
and 1.06 for AT; 0.99, 1.01, and 0.99 for 2-AT and 1.05, 0.98, and
0.96 for 4-AT at low, middle and high QC levels, respectively.
Moreover, the CVs of absolute matrix factor and ISTD normalized
matrix factor for all analytes from six lots of plasma samples
were less than 4.9%. These data indicated that ion suppression
or enhancement from the human plasma was negligible under the
current conditions.3.2.6. Stability studies
The results of stability tests evaluated following the procedures
described above (data not shown) point out that all analytes spiked
into human plasma were stable for at least 6.12 h in ice-cold water
bath, in an autosampler post extraction for 49 h at 5 1C, in plasma
placed at 50 1C for 103 days, and in plasma after three freeze–
thaw cycles (50 1C to ice-cold water bath). The stock solutions
of all analytes and ISTDs were found stable at 20 1C for 17 days
and the working solutions of all analytes and ISTDs were found
stable for about 9 h at room temperature.3.3. Method application
This developed method was applied to a pharmacokinetic study of
AT in 18 healthy adult male volunteers following oral adminis-
tration of 80 mg of AT tablet. The mean concentration–time proﬁle
of AT, 2-AT and 4-AT in these volunteers is shown in Fig. 4 and
the mean estimated pharmacokinetic parameters derived from the
plasma concentration proﬁles are summarized in Table 2. The
bioequivalence parameters almost overlapped between the test and
reference samples. The results of ISR, showing that 100.0%,
97.9%, and 95.7% of sample points for AT, 2-AT and 4-AT,
respectively, were within 720% of initial concentration value,
further proving the proposed method is reproducible and suitable
for pharmacokinetic evaluation of AT.ermination of AT, 2-AT, and 4-AT.
Inter-day (n¼18)
cy (%) CV (%) Mean (ng/mL) Accuracy (%) CV (%)
4.9 0.049 98.7 3.5
4.6 0.126 101.1 3.0
2.0 13.202 103.0 1.5
1.7 78.534 97.9 1.8
2.8 0.051 101.8 4.9
5.2 0.126 99.3 4.0
1.3 12.525 98.4 1.9
1.2 77.154 97.0 2.1
4.7 0.051 102.0 6.6
2.6 0.124 98.4 3.5
3.4 1.068 97.0 3.1
2.7 3.901 98.7 2.2
Fig. 4 The linear plasma mean concentration versus time proﬁle of (A) AT, (B) 2-AT, and (C) 4-AT. (R: reference formulation; T: test
formulation).
Fig. 3 Representative chromatograms of (1) AT, (2) 2-AT, and (3) 4-AT in human plasma: (A, E, I) blank; (B, F, J) blankþISTD; (C, G, K) LLOQ;
and (D, H, L) ULOQ. AT and AT-D5 (left panels, A–D); 2-AT and 2-AT-D5 (middle panels, E–H); 4-AT and 4-AT-D5 (right panels, I–L).
P. Partani et al.344. Conclusions
We developed and validated an LC–MS/MS method with ESI
interface using negative ion mode for simultaneous determination
of AT and its two hydroxyl metabolites (i.e., 2-AT and 4-AT) inhuman plasma. Use of deuterated ISTDs guaranteed the success of
the assay by eliminating the impact of matrix effects. Fused-cores
C18 column chemistry, together with methanol–acetonitrile mix-
ture as eluent in mobile phase, enhanced the separation capability
of the positional isomers, improved the assay sensitivity, and
Table 2 Pharmacokinetic parameters (mean7SD) of atorvastatin, after the administration of an oral dose of 80 mg test or reference
formulations to healthy Indian male volunteers.
Parameters AT 2-AT 4-AT
Reference Test Reference Test Reference Test
Tmax (h) 2.1371.20 1.8571.18 2.4671.20 2.5571.73 8.0173.93 10.0678.10
Cmax (ng/mL) 74.94756.01 70.60735.89 27.78714.88 31.75721.59 1.8571.52 2.3072.65
AUC0-t (ng h/mL) 3297229 3147134 2557151 2677132 47748 49735
AUC0-1 (ng h/mL) 3347229 3197135 2597151 2727132 68764 64739
t1/2 (h) 10.9672.81 12.3673.38 15.51710.15 12.7473.35 19.4574.25 23.3077.88
LC–MS/MS estimation of atorvastatin 35shortened the running time. In addition proposed SPE procedure
was simple, efﬁcient and easy to automate. Moreover, our
established method proved applicable to pharmacokinetic study,
thus providing an efﬁcient and robust support for further clinical
studies.
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